Category BUSINESS

Organon’s

Organon’s VTAMA® cream strongly recommended in 2026 pediatric eczema guidelines

Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis Organon a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced…

Read MoreOrganon’s VTAMA® cream strongly recommended in 2026 pediatric eczema guidelines

Sutter Health Broadens Deployment of Wearable Ultrasound Technology Across More Bay Area Hospitals to Advance Sepsis Care

Sutter Health Expands Use of Wearable Ultrasound Tech Across Additional Bay Area Hospitals to Advance Sepsis Care Sutter Health is expanding the use of FloPatch, the first wireless, wearable Doppler ultrasound device, across three additional Northern California hospitals: Sutter Solano…

Read MoreSutter Health Broadens Deployment of Wearable Ultrasound Technology Across More Bay Area Hospitals to Advance Sepsis Care
Abcuro

Kardigan reported positive Phase 2 data for tonlamarsen in uncontrolled hypertension at ACC.26, published in JACC

Kardigan Announces Positive Phase 2 Data for Tonlamarsen in Patients with Uncontrolled Hypertension Presented as Late-Breaker at ACC.26 and Simultaneously Published in JACC Kardigan™, a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases…

Read MoreKardigan reported positive Phase 2 data for tonlamarsen in uncontrolled hypertension at ACC.26, published in JACC
Alpha

Alpha Cognition reports fiscal 2025 results and operational update

Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update Alpha Cognition Inc. a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today reported financial results for the fourth quarter and full year ended December 31, 2025,…

Read MoreAlpha Cognition reports fiscal 2025 results and operational update
Turn Therapeutics

Turn Therapeutics raises up to $25 million in funding from Avenue Capital Group.

Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group Turn Therapeutics, Inc. a clinical-stage dermatology company developing novel therapies for inflammatory skin diseases, today announced it has entered into a growth capital loan facility with Avenue…

Read MoreTurn Therapeutics raises up to $25 million in funding from Avenue Capital Group.
Almirall’s

Almirall’s 17th Skin Academy spotlights advances in inflammatory skin diseases and skin cancer.

Almirall’s 17th Skin Academy Highlights Scientific Advances in Inflammatory Skin Diseases and Skin Cancer, Patient-Reported Outcomes, and Holistic Care in Medical Dermatology Almirall, a global biopharmaceutical company dedicated to medical dermatology, this weekend hosted the 17th edition of Skin Academy,…

Read MoreAlmirall’s 17th Skin Academy spotlights advances in inflammatory skin diseases and skin cancer.
Ionis

Ionis Pharmaceuticals: FDA Grants Priority Review for Zilganersen in Alexander disease

Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review Ionis Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for zilganersen, an…

Read MoreIonis Pharmaceuticals: FDA Grants Priority Review for Zilganersen in Alexander disease
Aledade

Enterprise Products Partners Publishes 2025 Investor Letter

Enterprise Products Partners Shares 2025 Investor Letter Highlighting Strategic Growth, Market Outlook, and Operational Performance. Enterprise Products Partners L.P. has released its 2025 Letter to Investors, providing stakeholders with insights into the partnership’s operational performance, strategic priorities, and long-term outlook.…

Read MoreEnterprise Products Partners Publishes 2025 Investor Letter